Showing results (1211-1220 of 4,506) with videos related to

Sort By:
Pageof 451
Advances in Therapy|February 4, 2022
Evaluation of Patient-Reported Satisfaction and Clinical Efficacy of Once-Weekly Semaglutide in Patients with Type 2 Diabetes: An Ambispective StudyAyman A Al Hayek, Mohamed A Al Dawish
Advances in Therapy|February 12, 2022
Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24 MonthsHidenobu Tanihara, Takahiko Kakuda, Tetsuro Sano, et al.
Advances in Therapy|October 5, 2021
Inpatient Hospital Costs for COVID-19 Patients in the United StatesRobert L Ohsfeldt, Casey Kar-Chan Choong, Patrick L Mc Collam, et al.
Advances in Therapy|February 22, 2022
Genotype-Guided Prescription of Azathioprine Reduces the Incidence of Adverse Drug Reactions in TPMT Intermediate Metabolizers to a Similar Incidence as Normal MetabolizersAna Casajús, Pablo Zubiaur, Marta Méndez, et al.
Advances in Therapy|February 24, 2022
Treatment Failure in Axial Spondyloarthritis: Insights for a Standardized DefinitionXavier Juanola, Manuel J Moreno Ramos, Joaquin Maria Belzunegui, et al.
Advances in Therapy|January 24, 2022
A New Approach to the Management of COVID-19. Antagonists of IL-6: SiltuximabLucinda Villaescusa, Francisco Zaragozá, Irene Gayo-Abeleira, et al.
Advances in Therapy|January 24, 2022
Fall Risk, Healthcare Resource Use, and Costs Among Adult Patients in the United States Treated for Insomnia with Zolpidem, Trazodone, or Benzodiazepines: A Retrospective Cohort StudyDiana T Amari, Timothy R Juday, Feride H Frech, et al.
Advances in Therapy|January 26, 2022
How to Choose the Right Inhaler Using a Patient-Centric Approach?Didier Cataldo, Shane Hanon, Rudi V Peché, et al.
Advances in Therapy|January 24, 2022
Budget Impact Analysis of Impella CP® Utilization in the Management of Cardiogenic Shock in France: A Health Economic AnalysisClément Delmas, Mathieu Pernot, Alexandre Le Guyader, et al.
Advances in Therapy|October 26, 2021
Neoadjuvant Therapy with Concurrent Docetaxel, Epirubicin, and Cyclophosphamide (TEC) in High-Risk HER2-Negative Breast CancersBryan Li, Thomas Yau, Roland Leung, et al.
Pageof 451